{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Trevi Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"TRVI"},"Address":{"label":"Address","value":"195 CHURCH STREET,14TH FLOOR 16TH FLOOR, NEW HAVEN, Connecticut, 06510, United States"},"Phone":{"label":"Phone","value":"+1 203 304-2499"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.trevitherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Danine Summers","title":"Vice President-Medical Affairs"},{"name":"Jennifer L. Good","title":"President, Chief Executive Officer & Director"},{"name":"Paula D. Buckley","title":"VP-Clinical Operations"},{"name":"Thomas R. Sciascia","title":"Chief Science Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}